Evommune Targets IPO in Divided Biopharmaceutical Sector
Written by Emily J. Thompson, Senior Investment Analyst
Source: stockanalysis
Updated: Oct 14 2025
0mins
Source: stockanalysis
IPO Plans: Evommune, Inc. is planning to raise $100 million through an initial public offering (IPO) to support its development of treatments for inflammatory diseases.
Lead Candidate: The company's primary candidate, EVO756, is currently undergoing Phase 2 trials aimed at treating chronic spontaneous urticaria.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
